CA2729248A1 - Rapid responses to delayed booster immunisations - Google Patents

Rapid responses to delayed booster immunisations Download PDF

Info

Publication number: CA2729248A1
Authority: CA; Canada
Prior art keywords: pathogen; subject; immune response; response against; boosting
Prior art date: 2008-06-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2729248A

Other languages

English (en)

French (fr)

Inventor

Giuseppe Del Giudice

Rino Rappuoli

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-25

Filing date

2009-06-25

Publication date

2009-12-30

2009-06-25 Application filed by Novartis AG filed Critical Novartis AG

2009-12-30 Publication of CA2729248A1 publication Critical patent/CA2729248A1/en

Status Abandoned legal-status Critical Current

Links

238000002649 immunization Methods 0.000 title abstract description 16
230000004044 response Effects 0.000 title abstract description 7
230000003111 delayed effect Effects 0.000 title description 3
244000052769 pathogen Species 0.000 claims abstract description 87
230000028993 immune response Effects 0.000 claims abstract description 82
230000001717 pathogenic effect Effects 0.000 claims abstract description 82
230000001681 protective effect Effects 0.000 claims abstract description 40
208000015181 infectious disease Diseases 0.000 claims abstract description 27
239000000203 mixture Substances 0.000 claims description 98
230000037452 priming Effects 0.000 claims description 73
230000002163 immunogen Effects 0.000 claims description 67
229960005486 vaccine Drugs 0.000 claims description 67
238000000034 method Methods 0.000 claims description 25
239000002671 adjuvant Substances 0.000 claims description 18
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 13
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 13
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 13
229940031439 squalene Drugs 0.000 claims description 13
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 13
230000005875 antibody response Effects 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 6
241000193985 Streptococcus agalactiae Species 0.000 claims description 5
210000000987 immune system Anatomy 0.000 claims description 5
241000712431 Influenza A virus Species 0.000 claims description 3
241000193996 Streptococcus pyogenes Species 0.000 claims description 3
239000000568 immunological adjuvant Substances 0.000 claims description 3
230000003472 neutralizing effect Effects 0.000 claims description 3
239000007764 o/w emulsion Substances 0.000 claims description 3
239000004094 surface-active agent Substances 0.000 claims description 3
241000589291 Acinetobacter Species 0.000 claims description 2
241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
241000193163 Clostridioides difficile Species 0.000 claims description 2
241000588724 Escherichia coli Species 0.000 claims description 2
241000588747 Klebsiella pneumoniae Species 0.000 claims description 2
241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
241000191940 Staphylococcus Species 0.000 claims description 2
241000191967 Staphylococcus aureus Species 0.000 claims description 2
108010029566 avian influenza A virus hemagglutinin Proteins 0.000 claims description 2
230000003571 opsonizing effect Effects 0.000 claims description 2
230000003053 immunization Effects 0.000 abstract description 17
230000036039 immunity Effects 0.000 abstract description 9
230000006698 induction Effects 0.000 abstract description 4
239000000839 emulsion Substances 0.000 description 19
238000002255 vaccination Methods 0.000 description 13
108010084884 GDP-mannose transporter Proteins 0.000 description 8
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
229920000053 polysorbate 80 Polymers 0.000 description 8
210000001806 memory b lymphocyte Anatomy 0.000 description 6
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
-1 into the arm or leg) Substances 0.000 description 5
GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 4
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
229960003971 influenza vaccine Drugs 0.000 description 4
239000007943 implant Substances 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
239000011707 mineral Substances 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
241000894007 species Species 0.000 description 3
238000012360 testing method Methods 0.000 description 3
235000010384 tocopherol Nutrition 0.000 description 3
229960001295 tocopherol Drugs 0.000 description 3
229930003799 tocopherol Natural products 0.000 description 3
239000011732 tocopherol Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
241000272525 Anas platyrhynchos Species 0.000 description 2
108010060123 Conjugate Vaccines Proteins 0.000 description 2
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
239000011627 DL-alpha-tocopherol Substances 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
206010041925 Staphylococcal infections Diseases 0.000 description 2
229940032047 Tdap vaccine Drugs 0.000 description 2
241000700605 Viruses Species 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
229940031670 conjugate vaccine Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001631 haemodialysis Methods 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
230000000322 hemodialysis Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
241000193449 Clostridium tetani Species 0.000 description 1
241000186227 Corynebacterium diphtheriae Species 0.000 description 1
206010011409 Cross infection Diseases 0.000 description 1
229940032024 DPT vaccine Drugs 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000295146 Gallionellaceae Species 0.000 description 1
241001493149 Gamboa virus Species 0.000 description 1
241000252870 H3N2 subtype Species 0.000 description 1
229940124870 Hepatitis A virus vaccine Drugs 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
241000713196 Influenza B virus Species 0.000 description 1
229940124873 Influenza virus vaccine Drugs 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029803 Nosocomial infection Diseases 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
229940124859 Rotavirus vaccine Drugs 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
201000003740 cowpox Diseases 0.000 description 1
239000002577 cryoprotective agent Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229960005097 diphtheria vaccines Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
230000000694 effects Effects 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
229940031689 heterologous vaccine Drugs 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
229940029583 inactivated polio vaccine Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229940041323 measles vaccine Drugs 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940095293 mumps vaccine Drugs 0.000 description 1
229960002566 papillomavirus vaccine Drugs 0.000 description 1
230000032696 parturition Effects 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229960003131 rubella vaccine Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
229960002766 tetanus vaccines Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
229940021648 varicella vaccine Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003501 vero cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Virology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

CA2729248A 2008-06-25 2009-06-25 Rapid responses to delayed booster immunisations Abandoned CA2729248A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13314008P	2008-06-25	2008-06-25
US61/133,140		2008-06-25
PCT/IB2009/006260 WO2009156852A1 (en)	2008-06-25	2009-06-25	Rapid responses to delayed booster immunisations

Publications (1)

Publication Number	Publication Date
CA2729248A1 true CA2729248A1 (en)	2009-12-30

Family

ID=41171092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2729248A Abandoned CA2729248A1 (en)	2008-06-25	2009-06-25	Rapid responses to delayed booster immunisations

Country Status (5)

Country	Link
US (1)	US9421251B2 (2)
EP (1)	EP2310045A1 (2)
JP (1)	JP5712126B2 (2)
CA (1)	CA2729248A1 (2)
WO (1)	WO2009156852A1 (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE047796T2 (hu)	2010-07-06	2020-05-28	Glaxosmithkline Biologicals Sa	RNS bevitele több immunútvonal bekapcsolására
PL2591114T3 (pl)	2010-07-06	2017-08-31	Glaxosmithkline Biologicals Sa	Immunizacja dużych ssaków małymi dawkami rna
HUE026646T2 (en)	2010-07-06	2016-07-28	Glaxosmithkline Biologicals Sa	Preferred liposomes containing lipids of PKA value for delivery of RNA
PT3970742T (pt)	2010-08-31	2022-06-27	Glaxosmithkline Biologicals Sa	Lipossomas peguilados para entrega de arn codificador de imunogénio
JP2013544504A (ja)	2010-10-11	2013-12-19	ノバルティスアーゲー	抗原送達プラットフォーム
AR086199A1 (es)	2011-04-22	2013-11-27	Wyeth Llc	Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US11058762B2 (en)	2011-07-06	2021-07-13	Glaxosmithkline Biologicals Sa	Immunogenic compositions and uses thereof
WO2013006838A1 (en)	2011-07-06	2013-01-10	Novartis Ag	Immunogenic combination compositions and uses thereof
BR122016023101B1 (pt)	2012-10-21	2022-03-22	Pfizer Inc	Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP4168032A2 (en)	2020-06-19	2023-04-26	Pfizer Inc.	Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9923176D0 (en)	1999-09-30	1999-12-01	Smithkline Beecham Biolog	Novel composition
CA2439111A1 (en)	2001-04-05	2002-10-17	Chiron Corporation	Mucosal boosting following parenteral priming
US8080255B2 (en)	2003-07-11	2011-12-20	Novavax Inc.	Functional influenza virus like particles (VLPs)
TWI365074B (en)	2004-10-07	2012-06-01	Wyeth Corp	Multivalent avian influenza vaccines
WO2006050394A2 (en)	2004-11-01	2006-05-11	Novartis Vaccines And Diagnostics Inc.	Combination approaches for generating immune responses
PT1861120T (pt)	2005-03-23	2016-08-18	Glaxosmithkline Biologicals Sa	Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
US20100158943A1 (en) *	2005-11-04	2010-06-24	Novartis Vaccines And Diagnostics Srl	Administration routes for priming/boosting with influenza vaccines
US20090304742A1 (en) *	2005-11-04	2009-12-10	Novartis Vaccines And Diagnostics Srl	Influenza vaccines with reduced amount of emulsion adjuvant
US9101578B2 (en)	2006-05-01	2015-08-11	Technovax, Inc.	Polyvalent influenza virus-like particle (VLP) compositions
US20080014217A1 (en)	2006-07-17	2008-01-17	Emmanuel Jules Hanon	Influenza vaccine
HRP20140488T1 (hr)	2006-07-17	2014-07-04	Glaxosmithkline Biologicals S.A.	Cjepivo protiv influence
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination

2009
- 2009-06-25 JP JP2011515663A patent/JP5712126B2/ja not_active Expired - Fee Related
- 2009-06-25 EP EP09769663A patent/EP2310045A1/en not_active Withdrawn
- 2009-06-25 WO PCT/IB2009/006260 patent/WO2009156852A1/en not_active Ceased
- 2009-06-25 US US12/999,848 patent/US9421251B2/en not_active Expired - Fee Related
- 2009-06-25 CA CA2729248A patent/CA2729248A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20110150931A1 (en)	2011-06-23
WO2009156852A1 (en)	2009-12-30
JP5712126B2 (ja)	2015-05-07
JP2011525902A (ja)	2011-09-29
US9421251B2 (en)	2016-08-23
EP2310045A1 (en)	2011-04-20

Legal Events

Date	Code	Title	Description
2014-06-17	EEER	Examination request	Effective date: 20140612
2018-04-24	FZDE	Discontinued	Effective date: 20180313

Publication	Publication Date	Title
US9421251B2 (en)	2016-08-23	Rapid responses to delayed booster immunisations
US20230390381A1 (en)	2023-12-07	Immunogenic combinations
Huckriede et al.	2005	The virosome concept for influenza vaccines
US9700605B2 (en)	2017-07-11	Vaccine comprising an oil in water emulsion
US20090081253A1 (en)	2009-03-26	Composition
KR20160079140A (ko)	2016-07-05	Ｈ5 인플루엔자 ａ 바이러스의 다수의 클레이드를 이용한 백신접종
CA2752809A1 (en)	2010-08-26	Inactivated dengue virus vaccine with aluminium-free adjuvant
US20150202283A1 (en)	2015-07-23	Method for eliciting in infants an immune response against rsv and b. pertussis
BE1022008B1 (fr)	2016-02-03	Compositions immunogenes combinees
Cyr et al.	2007	Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology
WO2014024026A1 (en)	2014-02-13	Method for eliciting in infants an immune response against rsv and b. pertussis
JP5918870B2 (ja)	2016-05-18	インフルエンザに対する改善されたワクチン接種
US20120219605A1 (en)	2012-08-30	Adjuvanted nanoparticulate influenza vaccine
EP2086582B1 (en)	2012-11-14	Vaccine comprising an oil in water emulsion adjuvant
WO2020067302A1 (ja)	2020-04-02	粘膜アジュバント
BRPI0609519A2 (pt)	2011-10-18	composição, uso de uma composição, método de vacinação, uso de um antìgeno, e, método para a preparação de uma composição imunogênica
AU2014200047A1 (en)	2014-01-30	Inactivated dengue virus vaccine with aluminium-free adjuvant
NZ575471A (en)	2011-06-30	Vaccine comprising an oil in water emulsion adjuvant